Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Shares Outstanding (Diluted Average): 2009-2025

Historic Shares Outstanding (Diluted Average) for Ani Pharmaceuticals (ANIP) over the last 17 years, with Sep 2025 value amounting to $21.1 million.

  • Ani Pharmaceuticals' Shares Outstanding (Diluted Average) rose 8.70% to $21.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.1 million, marking a year-over-year increase of 8.70%. This contributed to the annual value of $19.3 million for FY2024, which is 6.18% up from last year.
  • As of Q3 2025, Ani Pharmaceuticals' Shares Outstanding (Diluted Average) stood at $21.1 million, which was up 3.87% from $20.3 million recorded in Q2 2025.
  • Ani Pharmaceuticals' 5-year Shares Outstanding (Diluted Average) high stood at $21.1 million for Q3 2025, and its period low was $12.0 million during Q1 2021.
  • Moreover, its 3-year median value for Shares Outstanding (Diluted Average) was $19.4 million (2024), whereas its average is $19.2 million.
  • Data for Ani Pharmaceuticals' Shares Outstanding (Diluted Average) shows a peak YoY skyrocketed of 34.66% (in 2022) over the last 5 years.
  • Quarterly analysis of 5 years shows Ani Pharmaceuticals' Shares Outstanding (Diluted Average) stood at $12.6 million in 2021, then grew by 29.09% to $16.3 million in 2022, then rose by 11.89% to $18.2 million in 2023, then climbed by 6.18% to $19.3 million in 2024, then grew by 8.70% to $21.1 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $21.1 million for Q3 2025, versus $20.3 million for Q2 2025 and $20.0 million for Q1 2025.